ArriVent BioPharma, Inc.
AVBP
$22.86
$0.050.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -106.62% | -86.28% | -82.67% | -70.91% | -16.09% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 195.95% | 281.79% | 274.20% | 258.49% | 258.44% |
| Change in Net Operating Assets | -153.40% | -151.95% | -39.58% | -80.74% | -43.89% |
| Cash from Operations | -128.72% | -111.80% | -86.03% | -107.66% | -25.73% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 62.99% | -869.98% | -666.94% | -- | -- |
| Cash from Investing | 62.99% | -869.98% | -666.94% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8.87% | -9.83% | -55.55% | -95.83% | 52,606.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 96.05% | 85.38% | 97.93% | -- |
| Cash from Financing | 8.83% | -9.21% | -55.16% | -95.80% | 335.34% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 62.21% | -220.27% | -232.00% | -312.44% | -486.12% |